To study the metabolic phenotype of these aggressive B-cell lymphomas, we generated CD37-deficient human DLBCL cell lines (BJAB, OciLy1) using CRISPR/Cas9 technology and used a CD37-deficient mouse model20. The gene discussed is CD37; the disease is diffuse large B-cell lymphoma.